• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.器官移植受者严重急性呼吸综合征冠状病毒 2 再感染的纵向免疫分析。
J Infect Dis. 2022 Feb 1;225(3):374-384. doi: 10.1093/infdis/jiab553.
2
Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.案例研究:一名实体器官移植受者中新冠病毒再次感染的纵向免疫分析
medRxiv. 2021 Mar 26:2021.03.24.21253992. doi: 10.1101/2021.03.24.21253992.
3
Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.实体器官移植受者中新冠病毒再次感染的纵向免疫分析
Res Sq. 2021 May 5:rs.3.rs-405958. doi: 10.21203/rs.3.rs-405958/v1.
4
Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.COVID-19 疾病的恢复情况和免疫:预测再次感染潜力的新策略。
J Adv Res. 2021 Jul;31:49-60. doi: 10.1016/j.jare.2020.12.013. Epub 2021 Jan 5.
5
Reinfection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to reinfection.实体器官移植受者中 SARS-CoV-2 的再感染:再感染前的发病率密度和恢复期免疫。
Transpl Infect Dis. 2022 Jun;24(3):e13827. doi: 10.1111/tid.13827. Epub 2022 Apr 6.
6
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.新型冠状病毒感染后长达13个月的抗体反应演变及再次感染风险。
EBioMedicine. 2021 Sep;71:103561. doi: 10.1016/j.ebiom.2021.103561. Epub 2021 Aug 27.
7
SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.SARS-CoV-2 再感染,尽管存在可检测的中和抗体。
Viruses. 2021 Apr 12;13(4):661. doi: 10.3390/v13040661.
8
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.在无症状至轻症 COVID-19 感染至少 8 个月后,仍能产生强大的体液和细胞免疫反应,并降低再次感染的风险。
J Intern Med. 2022 Jan;291(1):72-80. doi: 10.1111/joim.13387. Epub 2021 Sep 27.
9
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.一名具有缺陷性中和体液反应的癌症患者出现严重急性呼吸综合征冠状病毒2型再次感染。
J Med Virol. 2021 Dec;93(12):6444-6446. doi: 10.1002/jmv.27200. Epub 2021 Jul 20.
10
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.SARS-CoV-2 的持久免疫控制和预防再感染的前景。
Nat Rev Immunol. 2021 Jun;21(6):395-404. doi: 10.1038/s41577-021-00550-x. Epub 2021 Apr 29.

引用本文的文献

1
Clinical and immunological insights into SARS-CoV-2 reinfection: a propensity score-matched cohort study.对严重急性呼吸综合征冠状病毒2型再次感染的临床和免疫学见解:一项倾向评分匹配队列研究。
BMC Infect Dis. 2025 Aug 1;25(1):970. doi: 10.1186/s12879-025-11398-0.
2
Laboratory Diagnosis for SARS-CoV-2 Infection.SARS-CoV-2 感染的实验室诊断。
Infect Dis Clin North Am. 2022 Jun;36(2):327-347. doi: 10.1016/j.idc.2022.02.002.
3
Reinfection in patients with COVID-19: a systematic review.COVID-19 患者再感染:系统评价。
Glob Health Res Policy. 2022 Apr 29;7(1):12. doi: 10.1186/s41256-022-00245-3.
4
The Effect of Varying Interval Definitions on the Prevalence of SARS-CoV-2 Reinfections: A Retrospective Cross-Sectional Cohort Study.不同间隔定义对SARS-CoV-2再感染患病率的影响:一项回顾性横断面队列研究。
Diagnostics (Basel). 2022 Mar 15;12(3):719. doi: 10.3390/diagnostics12030719.
5
SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.SARS-CoV-2 再次感染对全球疫苗接种运动的效果构成新挑战:对文献报告病例的系统评价。
Int J Environ Res Public Health. 2021 Oct 19;18(20):11001. doi: 10.3390/ijerph182011001.
6
The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients.实体器官移植受者中 SARS-CoV-2 感染和疫苗的免疫学
Viruses. 2021 Sep 20;13(9):1879. doi: 10.3390/v13091879.

本文引用的文献

1
Diagnosing SARS-CoV-2 with Antigen Testing, Transcription-Mediated Amplification and Real-Time PCR.通过抗原检测、转录介导扩增和实时聚合酶链反应诊断严重急性呼吸综合征冠状病毒2
J Clin Med. 2021 May 29;10(11):2404. doi: 10.3390/jcm10112404.
2
Protein-Based Immunome Wide Association Studies (PIWAS) for the Discovery of Significant Disease-Associated Antigens.基于蛋白质的免疫组学全基因组关联研究(PIWAS)在发现重要疾病相关抗原中的应用。
Front Immunol. 2021 Apr 27;12:625311. doi: 10.3389/fimmu.2021.625311. eCollection 2021.
3
Evaluation of the analytical performance and specificity of a SARS-CoV-2 transcription-mediated amplification assay.评估一种 SARS-CoV-2 转录介导扩增检测方法的分析性能和特异性。
J Virol Methods. 2021 Aug;294:114182. doi: 10.1016/j.jviromet.2021.114182. Epub 2021 May 10.
4
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.多种 SARS-CoV-2 变异株逃避疫苗诱导的体液免疫中和作用。
Cell. 2021 Apr 29;184(9):2372-2383.e9. doi: 10.1016/j.cell.2021.03.013. Epub 2021 Mar 12.
5
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.医护人员中抗SARS-CoV-2抗体状态及感染发生率
N Engl J Med. 2021 Feb 11;384(6):533-540. doi: 10.1056/NEJMoa2034545. Epub 2020 Dec 23.
8
B cell depletion therapies in autoimmune disease: advances and mechanistic insights.自身免疫性疾病中的 B 细胞耗竭疗法:进展与机制见解。
Nat Rev Drug Discov. 2021 Mar;20(3):179-199. doi: 10.1038/s41573-020-00092-2. Epub 2020 Dec 15.
9
Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response.比利时医院感染暴发中,一名医护人员出现有症状的严重急性呼吸综合征冠状病毒 2 再感染,尽管存在初级中和抗体反应。
Clin Infect Dis. 2021 Nov 2;73(9):e2985-e2991. doi: 10.1093/cid/ciaa1850.
10
Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity.新型冠状病毒长期RNA脱落及其与IgG血清阳性的时间关联。
Cell Death Discov. 2020 Dec 2;6(1):138. doi: 10.1038/s41420-020-00375-y.

器官移植受者严重急性呼吸综合征冠状病毒 2 再感染的纵向免疫分析。

Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.

机构信息

Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.

出版信息

J Infect Dis. 2022 Feb 1;225(3):374-384. doi: 10.1093/infdis/jiab553.

DOI:10.1093/infdis/jiab553
PMID:34718647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8807168/
Abstract

BACKGROUND

The underlying immunologic deficiencies enabling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection are currently unknown. We describe deep longitudinal immune profiling of a transplant recipient hospitalized twice for coronavirus disease 2019 (COVID-19).

METHODS

A 66-year-old male renal transplant recipient was hospitalized with COVID-19 March 2020 then readmitted to the hospital with COVID-19 233 days after initial diagnosis. Virologic and immunologic investigations were performed on samples from the primary and secondary infections.

RESULTS

Whole viral genome sequencing and phylogenetic analysis revealed that viruses causing both infections were caused by distinct genetic lineages without evidence of immune escape mutations. Longitudinal comparison of cellular and humoral responses during primary SARS-CoV-2 infection revealed that this patient responded to the primary infection with low neutralization titer anti-SARS-CoV-2 antibodies that were likely present at the time of reinfection.

CONCLUSIONS

The development of neutralizing antibodies and humoral memory responses in this patient failed to confer protection against reinfection, suggesting that they were below a neutralizing titer threshold or that additional factors may be required for efficient prevention of SARS-CoV-2 reinfection. Development of poorly neutralizing antibodies may have been due to profound and relatively specific reduction in naive CD4 T-cell pools. Seropositivity alone may not be a perfect correlate of protection in immunocompromised patients.

摘要

背景

目前尚不清楚导致严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 再感染的潜在免疫缺陷。我们描述了一名因 2019 年冠状病毒病 (COVID-19) 两次住院的移植受者的深度纵向免疫分析。

方法

一名 66 岁男性肾移植受者于 2020 年 3 月因 COVID-19 住院,初次诊断后 233 天因 COVID-19 再次入院。对原发性和继发性感染的样本进行了病毒学和免疫学调查。

结果

全病毒基因组测序和系统发育分析显示,导致两次感染的病毒均由不同的遗传谱系引起,没有免疫逃逸突变的证据。在初次 SARS-CoV-2 感染期间对细胞和体液反应的纵向比较表明,该患者对初次感染的反应是低中和效价的抗 SARS-CoV-2 抗体,这些抗体可能在再次感染时存在。

结论

该患者体内中和抗体和体液记忆反应的发展未能提供针对再感染的保护,这表明它们的中和效价低于阈值,或者可能需要其他因素才能有效预防 SARS-CoV-2 的再感染。中和抗体产生不良可能是由于幼稚 CD4 T 细胞库严重且相对特异性减少所致。在免疫功能低下的患者中,血清阳性本身可能不是保护的完美相关因素。